Mineralys reported post hoc Launch-HTN results showing lorundrostat delivered meaningful blood pressure reductions and reduced albuminuria in CKD patients, with a favorable safety profile. CKD and non-CKD groups achieved SBP improvements, with 44% of CKD patients reaching SBP <130 mmHg versus 18% placebo, and a 52.2% UACR reduction in CKD with albuminuria. NDA review remains on track for December 2026, supporting a potential near-term regulatory catalyst.
MLYS reported successful Phase 3 and Phase 2 trial results for lorundrostat. Lorundrostat showed significant reductions in systolic blood pressure compared to placebo. Trials demonstrated favorable safety and tolerability profiles for lorundrostat. MLYS stock increased 65.70% following positive trial results. FDA cleared lorundrostat for future trials in obstructive sleep apnea.
MLYS shares surged 53% to $16.13 on trial results. Tests for Lorundrostat met primary endpoints in Phase 2 and 3. Overall U.S. market saw significant declines amid economic uncertainties. Inflation expectations rose to 3.1%, influencing market sentiment. Energy sector showed gains, contrasting with tech sector's losses.
Mineralys announced successful trials for blood pressure drug lorundrostat. Positive trial results may enhance MLYS’s market potential and investor confidence.
